For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Eisai’s US Unit to Collaborate with Polish Research Firm Selvita on Anticancer Agents
September 20, 2013
- MTPC Completes Acquisition of Medicago, Now Ready to Bolster Vaccine Development
September 20, 2013
- Ethical Drug Sales Up 5.7% in July: Crecon Report
September 20, 2013
- Daiichi Sankyo, Mitsubishi UFJ Capital Establish New Fund to Support Ventures in Japan
September 19, 2013
- Eslicarbazepine Monotherapy Meets Primary Endpoint in PIII Trials: DSP
September 19, 2013
- GSK to Return All Rights to EPO Biosimilar to JCR Pharmaceuticals
September 19, 2013
- Kyowa Kirin Aims for 10% Share in a Highly Competitive Market for Diabetes Treatments, but Onglyza’s Chances of Success Remain in Doubt
September 19, 2013
- Demand Growing for Transdermal Patches in Graying Japan, Drug Makers Gear Up for Development
September 18, 2013
- Otsuka’s Samsca Wins Add’l Indication for Fluid Retention in Liver Cirrhosis Patients; World’s 1st Such Approval
September 18, 2013
- Takeda Grants Arbor Exclusive Rights for Edarbi Family of Products in US
September 17, 2013
- Xalkori Significantly Extends PFS in Japanese Patients: Pfizer
September 17, 2013
- Chugai Launches Breast Cancer Drug Parjeta
September 13, 2013
- Eisai Launches Halaven in Russia, First Product to Be Marketed by Company
September 13, 2013
- Hisamitsu Initiates PII Study of Transdermal Ropinirole for RLS Treatment in Japan
September 13, 2013
- Generic Drug Market Shows Steady Growth in 1st Quarter; Eisai, Meiji Seika Pharma Report Sharpest Growth in Sales
September 13, 2013
- Taiho’s TS-1 Failed to Significantly Improve Survival of Patients in Second-Line Treatment
September 12, 2013
- Nippon Kayaku’s Filing of Remicade Biosimilar Heralds Age of Major Biologic Follow-Ons
September 12, 2013
- Ono to Set Up New Strategic Division for Nivolumab
September 12, 2013
- Merck Serono Launches Human Growth Hormone Preparation Saizen 12 mg Subcutaneous Injection
September 12, 2013
- Nichi-Iko, BioLab Tie Up on Generic Business in Thailand
September 11, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…